Literature DB >> 1665529

[Therapy of a malignant sympathetic paraganglioma of the organ of Zuckerkandl--a case report].

F Schuppert1, G F Scheumann, C Schöber, J Overbeck, T H Schürmeyer, H J Schmoll, H Dralle, A von zur Mühlen.   

Abstract

We present a case report on a 35-year-old patient in whom a malignant sympathetic paraganglioma of the organ of Zuckerkandl was the cause of severe hypertension with excessive perspiration at night. Since curative surgery was not possible medical treatment was initiated. Interferon alfa 2b (Intron A, Essex Pharma) and the somatostatin-analogue SMS 201-995 (Sandostatin, Sandoz) had no effect on catecholamine production and progression of the tumor. Treatment with alpha-methyl-para-tyrosin (MPT, [Metyrosin], Demser, MSD) turned out to be an effective and well tolerable therapy in this patient with peritoneal carcinosis. Clinical and hormonal progression of the paraganglioma resumed only after two years of therapy, which constitutes the longest documented period of time of successful MPT treatment. The superior efficacy of MPT in our patient should encourage postoperative medical treatment with MPT in malignant pheochromocytoma or malignant paraganglioma, particularly when the tumor turns out to be resistent to alpha blocking drugs.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1665529     DOI: 10.1007/bf01798547

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  14 in total

1.  Reversibility of catecholamine-induced dilated cardiomyopathy in a child with a pheochromocytoma.

Authors:  J Imperato-McGinley; T Gautier; K Ehlers; M A Zullo; D S Goldstein; E D Vaughan
Journal:  N Engl J Med       Date:  1987-03-26       Impact factor: 91.245

2.  Metastatic pheochromocytoma associated with multiple endocrine neoplasia syndrome type II.

Authors:  A H Chevinsky; J P Minton; J M Falko
Journal:  Arch Surg       Date:  1990-07

3.  A re-evaluation of dopamine excretion in phaeochromocytoma.

Authors:  P A Tippett; A J McEwan; D M Ackery
Journal:  Clin Endocrinol (Oxf)       Date:  1986-10       Impact factor: 3.478

Review 4.  alpha-Methyl-p-tyrosine: a review of its pharmacology and clinical use.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1981-02       Impact factor: 9.546

5.  [Preoperative diagnosis of suspected pheochromocytoma--retrospective assessment of diagnostic criteria].

Authors:  T Schürmeyer; H Dralle; F Schuppert; A von zur Mühlen
Journal:  Acta Med Austriaca       Date:  1988

6.  [Recurrent hypertensive crises and dyspnea following unilateral adrenalectomy in pheochromocytoma in a 44-year-old patient. Successful combination chemotherapy of malignant pheochromocytoma].

Authors:  B Saller; K Jacob; A Markl; F M Zwiebel; D Engelhardt; K Mann
Journal:  Internist (Berl)       Date:  1990-01       Impact factor: 0.743

7.  Treatment of malignant endocrine pancreatic tumors with human leukocyte interferon.

Authors:  B Eriksson; K Oberg; G Alm; A Karlsson; G Lundqvist; A Magnusson; L Wide; E Wilander
Journal:  Cancer Treat Rep       Date:  1987-01

8.  Scintigraphic localization of pheochromocytoma.

Authors:  J C Sisson; M S Frager; T W Valk; M D Gross; D P Swanson; D M Wieland; M C Tobes; W H Beierwaltes; N W Thompson
Journal:  N Engl J Med       Date:  1981-07-02       Impact factor: 91.245

9.  Alternative catecholamine pathways after tyrosine hydroxylase inhibition in malignant pheochromocytoma.

Authors:  O Kuchel; N T Buu; D J Edwards
Journal:  J Lab Clin Med       Date:  1990-04

Review 10.  Recent developments in the diagnosis and treatment of pheochromocytoma.

Authors:  S G Sheps; N S Jiang; G G Klee; J A van Heerden
Journal:  Mayo Clin Proc       Date:  1990-01       Impact factor: 7.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.